165 related articles for article (PubMed ID: 25267563)
1. Occurrence of pulmonary rheumatoid nodules following biological therapies.
Kovács A; Baksay B; Cserenyecz A; Molnár K; Takács M; Szekanecz Z
Clin Rheumatol; 2015 Sep; 34(9):1639-42. PubMed ID: 25267563
[TBL] [Abstract][Full Text] [Related]
2. Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series.
Talotta R; Atzeni F; Batticciotto A; Ditto MC; Gerardi MC; Sarzi-Puttini P
J Med Case Rep; 2018 Jun; 12(1):154. PubMed ID: 29859543
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).
Burmester GR; Feist E; Kellner H; Braun J; Iking-Konert C; Rubbert-Roth A
Ann Rheum Dis; 2011 May; 70(5):755-9. PubMed ID: 21187298
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of rituximab on pulmonary nodulosis occurring or increasing in patients with rheumatoid arthritis during anti-TNF-α therapy.
De Stefano R; Frati E; Nargi F; Menza L
Clin Exp Rheumatol; 2011; 29(4):752-3. PubMed ID: 21906436
[No Abstract] [Full Text] [Related]
5. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
Daïen CI; Gailhac S; Audo R; Mura T; Hahne M; Combe B; Morel J
Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
[TBL] [Abstract][Full Text] [Related]
6. A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study.
Nakagawa J; Koyama Y; Kawakami A; Ueki Y; Tsukamoto H; Horiuchi T; Nagano S; Uchino A; Ota T; Akahoshi M; Akashi K
Arthritis Res Ther; 2017 Aug; 19(1):185. PubMed ID: 28800780
[TBL] [Abstract][Full Text] [Related]
7. Rheumatoid lung nodulosis and osteopathy associated with leflunomide therapy.
Rozin A; Yigla M; Guralnik L; Keidar Z; Vlodavsky E; Rozenbaum M; Nahir AM; Balbir-Gurman A
Clin Rheumatol; 2006 May; 25(3):384-8. PubMed ID: 16211338
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
[TBL] [Abstract][Full Text] [Related]
9. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK
Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
[TBL] [Abstract][Full Text] [Related]
10. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
Tanaka Y; Takeuchi T; Amano K; Saito K; Hanami K; Nawata M; Fukuyo S; Kameda H; Kaneko Y; Kurasawa T; Nagasawa H; Hoshi D; Sato E; Yamanaka H
Mod Rheumatol; 2014 May; 24(3):399-404. PubMed ID: 24252045
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of rituximab in the treatment of pulmonary rheumatoid nodules: findings in 10 patients from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry (AIR/PR registry).
Glace B; Gottenberg JE; Mariette X; Philippe R; Pereira B; Lequerré T; Berthelot JM; Dougados M; Toussirot E; Pham T; Allanore Y; Loeuille D; Euller-Ziegler L; Soubrier M
Ann Rheum Dis; 2012 Aug; 71(8):1429-31. PubMed ID: 22504557
[No Abstract] [Full Text] [Related]
12. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study.
Caporali R; Idolazzi L; Bombardieri S; Ferraccioli G; Gerli R; Govoni M; Matucci Cerinic M; Pomponio G; Salaffi F; Tirri R; Benaglio F; Bianchino L; Sarzi-Puttini P;
Clin Exp Rheumatol; 2017; 35(6):919-928. PubMed ID: 28516890
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Kivitz A; Olech E; Borofsky M; Zazueta BM; Navarro-Sarabia F; Radominski SC; Merrill JT; Rowell L; Nasmyth-Miller C; Bao M; Wright S; Pope JE
Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1653-61. PubMed ID: 24942540
[TBL] [Abstract][Full Text] [Related]
15. Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice.
Kaufmann J; Feist E; Roske AE; Schmidt WA
Clin Rheumatol; 2013 Sep; 32(9):1347-55. PubMed ID: 23703358
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series.
Toussirot E; Berthelot JM; Pertuiset E; Bouvard B; Gaudin P; Wendling D; le Noach J; Lohse A; Lecuyer E; Cri L
J Rheumatol; 2009 Nov; 36(11):2421-7. PubMed ID: 19797509
[TBL] [Abstract][Full Text] [Related]
17. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
[TBL] [Abstract][Full Text] [Related]
18. Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis.
Boyce EG; Rogan EL; Vyas D; Prasad N; Mai Y
Ann Pharmacother; 2018 Aug; 52(8):780-791. PubMed ID: 29482351
[TBL] [Abstract][Full Text] [Related]
19. Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects.
Xue Y; Cohen JM; Wright NA; Merola JF
Am J Clin Dermatol; 2016 Apr; 17(2):147-62. PubMed ID: 26649439
[TBL] [Abstract][Full Text] [Related]
20. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
